See the DrugPatentWatch profile for Fasenra
Fasenra targets the alpha subunit of the interleukin-5 (IL-5) receptor [1]. IL-5 is a cytokine that plays a crucial role in the development, activation, and survival of eosinophils [2]. By binding to the IL-5 receptor on eosinophils, Fasenra inhibits the signaling pathways mediated by IL-5 [1]. This binding effectively depletes eosinophils in the blood, tissues, and bone marrow [2].
How does Fasenra reduce eosinophil levels?
Fasenra is a monoclonal antibody that specifically targets the alpha subunit of the IL-5 receptor [1]. When Fasenra binds to this receptor, it prevents IL-5 from attaching and signaling [1][2]. This blockade leads to a reduction in the number of eosinophils through several mechanisms, including increased apoptosis (programmed cell death) and reduced eosinophil recruitment [1][3]. Clinical studies have shown significant decreases in peripheral blood eosinophil counts in patients treated with Fasenra [2].
What is the role of IL-5 in the body?
Interleukin-5 (IL-5) is a key signaling molecule that is essential for the normal life cycle of eosinophils [2]. It is produced by T cells and mast cells, and it signals through receptors on eosinophils to promote their production in the bone marrow, their release into the bloodstream, their activation, and their survival [2][4]. In conditions like severe eosinophilic asthma, elevated levels of IL-5 contribute to the excessive accumulation and activity of eosinophils in the airways, which can lead to inflammation and exacerbations [4].
How does Fasenra work for severe eosinophilic asthma?
In severe eosinophilic asthma, eosinophils are believed to be a major driver of airway inflammation and disease exacerbations [4]. Fasenra's mechanism of action, which involves depleting eosinophils by blocking IL-5 signaling, directly addresses this underlying pathology [1][3]. By reducing the eosinophil burden, Fasenra aims to decrease airway inflammation, leading to fewer asthma attacks and an improvement in overall asthma control [2][4].
What are the potential side effects of Fasenra?
Common side effects associated with Fasenra treatment can include headache and injection site reactions [1]. More serious, though less common, side effects may involve hypersensitivity reactions [1]. Patients should report any new or worsening symptoms to their healthcare provider.
When does Fasenra patent exclusivity expire?
Information regarding specific patent expiry dates for Fasenra is available on DrugPatentWatch.com [5]. Patent expiry is a critical factor in determining when generic or biosimilar versions of a drug may become available [5].